# US 2023/0067202 A1 · Combination Treatments and Uses and Methods Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067202 A1
- Document ID: US20230067202A1
- Status: Published application
- Kind: A1
- Application number: 17/789,415
- Filed: 2021-01-28
- Published: 2023-03-02
- Earliest claimed: 2020-01-28
- Assignees: GlaxoSmithKline Intellectual Property Development Limited
- Applicants: Glaxosmithkline Intellectual Property Development Limited
- Inventors: Ira GUPTA; Axel HOOS
- Web page: https://patentgrep.com/patent/US20230067202A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/68031: {the drug being an auristatin}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are combinations of an antigen binding protein that binds BCMA with an antigen binding protein that bind to an immunomodulatory agent, such as PD-1, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combinations, including uses in cancer.

## Claims

### Claim 1

A method of treating cancer in a patient in need thereof comprising administering an antigen binding protein that binds BCMA and an antigen binding protein that binds PD-1 comprising CDRH1 of SEQ. ID. NO: 11, CDRH2 of SEQ. ID. NO: 12, CDRH3 of SEQ. ID. NO: 13, CDRL1 of SEQ. ID. NO: 14, CDRL2 of SEQ. ID. NO: 15, and CDRL3: SEQ. ID. NO: 16, or variants thereof.

### Claim 2 (depends on 1)

The method claim 1, wherein the antigen binding protein that binds BCMA comprises CDRH1 of SEQ. ID. NO: 1, CDRH2 of SEQ. ID. NO: 2, CDRH3 of SEQ. ID. NO: 3, CDRL1 of SEQ. ID. NO: 4, CDRL2 of SEQ. ID. NO: 5, and CDRL3: SEQ. ID. NO: 6, or variants thereof.

### Claim 3 (depends on 2)

The method of claim 2 wherein the antigen binding protein that binds BCMA is an antibody drug conjugate comprising and antibody linked to MMAF or MMAE.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antigen binding protein that binds BCMA is belantamab mafodotin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antigen binding protein that binds PD-1 is dostarlimab.

### Claim 6

A method of treating cancer in a patient in need thereof comprising administering belantamab mafodotin and dostarlimab.

### Claim 7 (depends on 6)

The method of claim 6, wherein belantamab mafodotin is administered at about 0.03 mg/kg to about 4.6 mg/kg and dostarlimab is administered at about 100 mg to about 2000 mg.

### Claim 8 (depends on 6)

The method of claim 6, wherein belantamab mafodotin is administered at about 0.95 mg/kg, about 1.9 mg/kg, about 2.5 mg/kg, or about 3.4 mg/kg.

### Claim 9 (depends on 6)

The method of claim 6, wherein dostarlimab is administered at about 500 mg.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is relapsed or refractory multiple myeloma.

### Claim 11 (depends on 10)

The method of claim 10, wherein the patient was previously treated with at least 3 prior lines of cancer therapy.

### Claim 12 (depends on 1)

The method of claim 1 wherein the patient is human.

### Claim 13 (depends on 1)

The method of claim 1, wherein belantamab mafodotin and dostarlimab are administered on day 1 of a 21-day cycle (Q3W).

### Claim 14

A method of treating multiple myeloma in a human in need thereof comprising administering on day 1 of a 21-day cycle (Q3W):
a) about 0.95 mg/kg, about 1.9 mg/kg, about 2.5 mg/kg, or about 3.4 mg/kg of belantamab mafodotin, and
b) about 500 mg of dostarlimab.

### Claim 15

A combination comprising an antigen binding protein that binds to BCMA and an antigen binding protein that binds PD-1 comprising CDRH1 of SEQ. ID. NO: 11, CDRH2 of SEQ. ID. NO: 12, CDRH3 of SEQ. ID. NO: 13, CDRL1 of SEQ. ID. NO: 14, CDRL2 of SEQ. ID. NO: 15, and CDRL3: SEQ. ID. NO: 16, or variants thereof.

### Claim 16

A combination comprising belantamab mafodotin and dostarlimab.

### Claim 17 (depends on 16)

The combination of claim 16, comprising about 0.95 mg/kg, about 1.9 mg/kg, about 2.5 mg/kg, or about 3.4 mg/kg belantamab mafodotin, and about 500 mg of dostarlimab

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The combination of claim 17, wherein the cancer is relapsed or refractory multiple myeloma.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

A kit comprising belantamab mafodotin and dostarlimab.

### Claim 23

A method for treating a B cell disorder in a human, the method comprising (i) administering from about 0.95 mg/kg to about 3.4 mg/kg of belantamab mafodotin; and, (ii) administering 500 mg of dostarlimab.
